Overall survival (OS) Duration of study (Up to 10 years) [clinicaltrials_resource:5504cc4b4f403dee6d77642690a6e005]
Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Overall survival (OS) Duration of study (Up to 10 years) [clinicaltrials_resource:5504cc4b4f403dee6d77642690a6e005]
Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
Bio2RDF identifier
5504cc4b4f403dee6d77642690a6e005
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:5504cc4b4f403dee6d77642690a6e005
measure [clinicaltrials_vocabulary:measure]
Overall survival (OS)
time frame [clinicaltrials_vocabulary:time-frame]
Duration of study (Up to 10 years)
description
Patients will receive a standa ...... taurin for twelve (12) months.
identifier
clinicaltrials_resource:5504cc4b4f403dee6d77642690a6e005
title
Overall survival (OS) Duration of study (Up to 10 years)
@en
type
label
Overall survival (OS) Duration ...... 4cc4b4f403dee6d77642690a6e005]
@en